Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 16, pp. 1500-1509
Open Access | Times Cited: 1423

Showing 1-25 of 1423 citing articles:

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Borja Ibáñez, Stefan James, Stefan Agewall, et al.
European Heart Journal (2017) Vol. 39, Iss. 2, pp. 119-177
Open Access | Times Cited: 8579
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
European Heart Journal (2019) Vol. 41, Iss. 1, pp. 111-188
Open Access | Times Cited: 6829
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
European Heart Journal (2016) Vol. 37, Iss. 29, pp. 2315-2381
Open Access | Times Cited: 5960
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Circulation (2019) Vol. 139, Iss. 25
Open Access | Times Cited: 5450
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 18, pp. 1713-1722
Open Access | Times Cited: 4966
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
François Mach, Colin Baigent, Alberico L. Catapano, et al.
Atherosclerosis (2019) Vol. 290, pp. 140-205
Open Access | Times Cited: 4166
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer, et al.
European Heart Journal (2016) Vol. 37, Iss. 39, pp. 2999-3058
Open Access | Times Cited: 2848
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 22, pp. 2097-2107
Open Access | Times Cited: 2803
Atherosclerosis
Peter Libby, Julie E. Buring, Lina Badimón, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 2206
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Journal of the American College of Cardiology (2018) Vol. 73, Iss. 24, pp. e285-e350
Open Access | Times Cited: 2092
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer, et al.
Atherosclerosis (2016) Vol. 253, pp. 281-344
Open Access | Times Cited: 1540
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall, et al.
European Journal of Preventive Cardiology (2016) Vol. 23, Iss. 11, pp. NP1-NP96
Open Access | Times Cited: 1148
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson, Jean Grégoire, Glen J. Pearson, et al.
Canadian Journal of Cardiology (2016) Vol. 32, Iss. 11, pp. 1263-1282
Closed Access | Times Cited: 1093
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Cecilia C. Low Wang, Connie N. Hess, William R. Hiatt, et al.
Circulation (2016) Vol. 133, Iss. 24, pp. 2459-2502
Open Access | Times Cited: 945
SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology
Hitoshi Shimano, Ryuichiro Sato
Nature Reviews Endocrinology (2017) Vol. 13, Iss. 12, pp. 710-730
Closed Access | Times Cited: 885
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 15, pp. 1430-1440
Open Access | Times Cited: 871
Metabolic syndrome update
Scott M. Grundy
Trends in Cardiovascular Medicine (2015) Vol. 26, Iss. 4, pp. 364-373
Closed Access | Times Cited: 758
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Terry A. Jacobson, Kevin C. Maki, Carl E. Orringer, et al.
Journal of clinical lipidology (2015) Vol. 9, Iss. 6, pp. S1-S122.e1
Open Access | Times Cited: 744
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, et al.
Endocrine Practice (2016) Vol. 22, Iss. 1, pp. 84-113
Open Access | Times Cited: 692
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
Makoto Kinoshita, Koutaro Yokote, Hidenori Arai, et al.
Journal of Atherosclerosis and Thrombosis (2018) Vol. 25, Iss. 9, pp. 846-984
Open Access | Times Cited: 691
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald, Suellen White, Anna Borodovsky, et al.
New England Journal of Medicine (2016) Vol. 376, Iss. 1, pp. 41-51
Open Access | Times Cited: 682
Variation inPCSK9andHMGCRand Risk of Cardiovascular Disease and Diabetes
Brian A. Ference, Jennifer G. Robinson, Robert D. Brook, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 22, pp. 2144-2153
Open Access | Times Cited: 669
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, et al.
Circulation (2017) Vol. 137, Iss. 4, pp. 338-350
Open Access | Times Cited: 663
The Agenda for Familial Hypercholesterolemia
Samuel S. Gidding, Mary Ann Champagne, Sarah D. de Ferranti, et al.
Circulation (2015) Vol. 132, Iss. 22, pp. 2167-2192
Closed Access | Times Cited: 609
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Paul M. Ridker, James H. Revkin, Pierre Amarenco, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 16, pp. 1527-1539
Open Access | Times Cited: 572
Page 1 - Next Page

Scroll to top